TrovaGene, Inc. (TROV): Price and Financial Metrics


TrovaGene, Inc. (TROV)

Today's Latest Price: $1.19 USD

0.01 (-0.83%)

Updated May 7 7:46pm

Add TROV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

TROV Stock Summary

  • TROV's price/sales ratio is 49.66; that's higher than the P/S ratio of 96.73% of US stocks.
  • As for revenue growth, note that TROV's revenue has grown -35.34% over the past 12 months; that beats the revenue growth of only 5.26% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TROV comes in at -99.74% -- higher than that of just 4.81% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Trovagene Inc, a group of peers worth examining would be ADXS, TNAV, DRRX, NOVN, and MEET.
  • Visit TROV's SEC page to see the company's official filings. To visit the company's web site, go to trovageneoncology.com.
TROV Daily Price Range
TROV 52-Week Price Range

TROV Stock Price Chart Technical Analysis Charts


TROV Price/Volume Stats

Current price $1.19 52-week high $3.46
Prev. close $1.20 52-week low $0.70
Day low $1.16 Volume 166,400
Day high $1.19 Avg. volume 648,892
50-day MA $1.05 Dividend yield N/A
200-day MA $1.47 Market Cap 13.10M

TrovaGene, Inc. (TROV) Company Bio


Trovagene, Inc. focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. The company was founded in 1999 and is based in San Diego, California.


TROV Latest News Stream


Event/TimeNews Detail
Loading, please wait...

TROV Latest Social Stream


Loading social stream, please wait...

View Full TROV Social Stream

Latest TROV News From Around the Web

Below are the latest news stories about Trovagene Inc that investors may wish to consider to help them evaluate TROV as an investment opportunity.

Trovagene Announces First Quarter 2020 Results and Highlights

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today announced company highlights and financial results for the first quarter ended March 31, 2020. The company is issuing this press release in lieu of conducting a conference call.

Yahoo | May 7, 2020

Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer

SAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant…

PR Newswire | May 6, 2020

Trovagene Announces Fourth Quarter and Full-Year 2019 Results

SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today…

PR Newswire | February 27, 2020

Trovagene Receives Approximately $1.45 Million From Exercise of Warrants

SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia,…

PR Newswire | January 29, 2020

Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH

SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today…

PR Newswire | December 9, 2019

Read More 'TROV' Stories Here

TROV Price Returns

1-mo N/A
3-mo 26.46%
6-mo -14.39%
1-year -43.87%
3-year -98.52%
5-year -99.84%
YTD -4.03%
2019 -60.63%
2018 -85.80%
2017 -85.33%
2016 -61.11%
2015 25.58%

Continue Researching TROV

Here are a few links from around the web to help you further your research on Trovagene Inc's stock as an investment opportunity:

Trovagene Inc (TROV) Stock Price | Nasdaq
Trovagene Inc (TROV) Stock Quote, History and News - Yahoo Finance
Trovagene Inc (TROV) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9408 seconds.